Share:
Non-Malaysian citizens are subject to 6% SST, to be verified and paid at the counter before screening.
CA15-3 Test — Breast Cancer Marker
Introduction
CA15-3 (Cancer Antigen 15-3) is a glycoprotein antigen commonly used as a tumor marker for breast cancer. It is most valuable in advanced or recurrent breast cancer, where CA15-3 levels are often significantly elevated.
Note: Elevated CA15-3 alone does not confirm breast cancer, as benign conditions such as mastitis, liver disease, or ovarian cysts may also raise levels.
Why Take a CA15-3 Test?
- Treatment monitoring: Track CA15-3 changes during therapy to assess effectiveness.
- Recurrence follow-up: Used post-treatment or post-surgery to monitor relapse risk.
- Risk indication: Complements imaging and other markers to increase clinical accuracy.
Method & Workflow
A venous blood sample is collected to measure CA15-3. Results should be interpreted with clinical history and imaging (ultrasound, mammogram, or MRI).
Factors & Notes
- Benign conditions (mastitis, liver disease, ovarian benign lesions) may elevate CA15-3.
- Early-stage breast cancer may not elevate CA15-3, limiting its role in early screening.
- Serial monitoring is more valuable than isolated measurements.
Who Should Consider Testing?
- Breast cancer patients under active treatment
- Post-treatment or post-surgery patients for recurrence surveillance
- Individuals advised by their doctor as part of a tumor marker panel
Frequently Asked Questions (FAQ)
Q1: Does high CA15-3 always mean breast cancer?
A: No. Benign diseases such as mastitis or liver disease can also increase CA15-3.
Q2: Is CA15-3 useful for early breast cancer screening?
A: No. Many early breast cancers show normal CA15-3 levels, so it is not reliable for screening alone.
Q3: How should CA15-3 results be interpreted?
A: Results should be evaluated alongside clinical examination and imaging (ultrasound, mammogram, MRI), focusing on trends over time.
Inquiry - Breast Cancer Marker CA15-3
